Erythropoietic porphyria (EP) belongs to the porphyria group of disorders. These arise from deficiencies in enzymes that catalyze steps in heme biosynthesis. Manifestations of the disease vary and depend on the metabolic intermediates that accumulate and the organs primarily affected. Based on the main organ involved, the porphyria diseases are classified into hepatic and erythroid groups [1].

EP is a very rare disease that arises because of a deficiency of uroporphyrinogen III synthase. This results in spontaneous formation of type I isomers (uroporphyrinogen I and uroporphyrin I); these are dead-end products, which accumulate mainly in red blood cells, plasma, and bone, and are excreted in urine and feces. Porphyrins are colored, fluoresce in UV light, and cause photosensitivity in biomolecules and damage to tissues.

EP is inherited as an autosomal recessive disorder. Manifestations range from severe cases, detected first as jaundice and pink diaper rash in newborns, or even earlier as intrauterine hydrops due to hemolytic anemia, to milder manifestations in adults.

A characteristic feature of the disease is damage, often severe, to the skin, especially in areas exposed to light (face, hands). There are bullous lesions, which rupture easily and become infected. Repeated damage and infections cause scarring, pigmentation, and thickening of the skin. Epidermal atrophy and destruction of cartilage lead to contractures, loss of digits, and deformities on the face and hands [2]. Hypertrichosis of the face is also common. Damage to the eye [3] may occur because of several reasons, among which are inflammation and lagophthalmos; scarring of the cornea may lead to visual loss or even blindness. The teeth can have a red color because of deposition of porphyrin in them. Porphyrins can also collect in the bones and cause bone loss and deformities.

Hemolysis, which occurs to varying degrees, is probably because the deposition of uroporphyrin I in erythrocytes renders them fragile. This effect leads to hemolytic anemia, splenomegaly, and thrombocytopenia. Compensatory bone marrow expansion can result in fragile bones [4].

Children or adults with skin blistering conditions should be tested for EP. Urinary excretion of porphyrins is increased excessively (100-1000 fold) in EP with about 90% being made up of type I isomers [5]. Concentrations of precursors (for example porphobilinogen) are unchanged. Large amounts of porphyrins (mainly coproporphyrins) also appear in the feces. Red blood cells and plasma also contain increased concentrations of porphyrins. Patients with the highest levels of porphyrins are most affected [5].

Both direct and coupled assays for uroporphyrinogen III synthase activity have been developed [6]. Prenatal diagnosis can be performed by measuring uroporphyrinogen III synthase enzyme activity in chorionic villi or cultured amniotic cells [7].

Detection of mutations in the synthase gene can also be used for prenatal diagnosis [8]. The mutations in uroporphyrinogen III synthase are heterogeneous, but there is one mutation (C73R) that is present in 40% of cases [9]. Homozygotes for this mutation have the most severe form of the disease; genotype-phenotype correspondence for other mutations has also been examined [2]. In addition to molecular analyses, examination of porphyrin levels should also be undertaken to assess the likely severity of the disease [10]. An elevated concentration of uroporphyrin I in the amniotic fluid is indicative of EP [8].

Fluorescence microscopy will detect fluorescing nuclei in erythrocyte precursors in EP. Histologic examinations demonstrate cutaneous changes (such as hyalinized walls of blood vessels and caterpillar bodies) that also occur in other porphyrias.

There is no cure for CEP, but treatment focuses on managing symptoms and preventing complications. Patients are advised to avoid sunlight exposure and use protective clothing and sunscreen. Blood transfusions may be necessary to manage anemia. In severe cases, bone marrow transplantation has been used as a treatment option. Regular follow-ups with a healthcare provider are essential to monitor the condition.

The prognosis for individuals with CEP varies. With proper management, many patients can lead relatively normal lives. However, severe cases can lead to significant complications, including skin damage and organ dysfunction. Early diagnosis and intervention are crucial in improving outcomes.

CEP is caused by mutations in the UROS gene, which provides instructions for making an enzyme involved in heme production. These mutations lead to a deficiency in the enzyme, causing the accumulation of porphyrins. The condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations.

CEP is an extremely rare condition, with only a few hundred cases reported worldwide. It affects both males and females equally and can occur in any ethnic group. Due to its rarity, the exact prevalence is not well-documented.

In CEP, the deficiency of the enzyme uroporphyrinogen III synthase leads to the accumulation of porphyrins in the bone marrow, blood, and other tissues. These porphyrins are photosensitive, meaning they react to light, causing damage to the skin and other tissues. The buildup of porphyrins also affects red blood cell production, leading to anemia.

As CEP is a genetic disorder, there is no known way to prevent it. Genetic counseling is recommended for families with a history of the condition to understand the risks and implications of passing the gene to offspring. Prenatal testing may be available for at-risk pregnancies.

Congenital Erythropoietic Porphyria is a rare genetic disorder characterized by photosensitivity, anemia, and other systemic symptoms due to the accumulation of porphyrins. While there is no cure, management focuses on symptom relief and prevention of complications. Early diagnosis and intervention are key to improving quality of life for affected individuals.

If you or a loved one has been diagnosed with Congenital Erythropoietic Porphyria, it's important to understand the condition and its implications. Protecting the skin from sunlight, managing anemia, and regular medical check-ups are crucial. Genetic counseling can provide valuable information for family planning. Remember, while CEP is a lifelong condition, with proper care, many individuals can lead fulfilling lives.

1. Gross U, Hoffmann GF, Doss MO. Erythropoietic and hepatic porphyrias. J Inherit Metab Dis. 2000 Nov;23(7):641-661.
2. Desnick RJ, Astrin KH. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Haematol. 2002 Jun;117(4):779-795.
3. Hillenkamp J, Reinhard T, Fritsch C, et. al. Ocular involvement in congenital erythropoietic porphyria (Günther's disease): cytopathological evaluation of conjunctival and corneal changes. Br J Ophthalmol. 2001 Mar; 85(3):371
4. Poh-Fitzpatrick MB. Clinical features of the porphyrias. Clin Dermatol. 1998 Mar-Apr;16(2):251-264.
5. Freesemann AG, Bhutani LK, Jacob K, Doss MO. Interdependence between degree of porphyrin excess and disease severity in congenital erythropoietic porphyria (Günther's disease). Arch Dermatol Res. 1997 Apr;289(5):272-276.
6. Tsai SF, Bishop DF, Desnick RJ. Coupled-enzyme and direct assays for uroporphyrinogen III synthase activity in human erythrocytes and cultured lymphoblasts. Enzymatic diagnosis of heterozygotes and homozygotes with congenital erythropoietic porphyria. Anal Biochem. 1987 Oct;166(1):120-133.
7. Deybach JC, Grandchamp B, Grelier M, et al. Prenatal exclusion of congenital erythropoietic porphyria (Günther's disease) in a fetus at risk. Hum Genet. 1980 Feb;53(2):217-221.
8. Ged C, Moreau-Gaudry F, Taine L, et. al. Prenatal diagnosis in congenital erythropoietic porphyria by metabolic measurement and DNA mutation analysis. Prenat Diagn. 1996 Jan;16(1):83-86.
9. Frank J, Wang X, Lam HM, et al. C73R is a hotspot mutation in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Ann Hum Genet. 1998 May;62(Pt 3):225-230.
10. Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol. 2006 Nov;135(3):281-292.